Repository Study of Autosomal Dominant Polycystic Kidney Disease
NCT01988038 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-03-29
Summary
The design and establishment of the Polycystic Kidney Disease (PKD) Data Repository does not require, and may be constrained by, a narrowly conceived hypothesis. However, the PKD Repository has been designed to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of the disorder and assess the factors that are likely to be associated with the progression of disease and the incidence of complications including renal failure, cardiovascular disease, and stroke.
Conditions
- Autosomal Dominant Polycystic Kidney Disease
Sponsors & Collaborators
-
Weill Medical College of Cornell University
collaborator OTHER -
New York Presbyterian Hospital
collaborator OTHER -
The Rogosin Institute
lead OTHER
Principal Investigators
-
Jon Blumenfeld, MD · The Rogosin Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-11-30
- Primary Completion
- 2016-06-30
- Completion
- 2016-06-30
Countries
- United States
Study Locations
More Related Trials
-
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
NCT00920309 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Genetic Testing to Understand and Address Renal Disease Disparities
NCT02234063 ·Status: COMPLETED ·Phase: NA
-
Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia
NCT00374712 ·Status: TERMINATED
-
Role of ROS and cAMP-PKA Biomarkers in ADPKD
NCT07217158 ·Status: ACTIVE_NOT_RECRUITING
-
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
NCT01221181 ·Status: COMPLETED ·Phase: PHASE1
-
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT04344769 ·Status: RECRUITING
-
Nephrotic Syndrome Study Network
NCT01209000 ·Status: RECRUITING
-
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
NCT00616902 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
NCT02112136 ·Status: COMPLETED ·Phase: NA
-
HALT Progression of Polycystic Kidney Disease Study B
NCT01885559 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of Mycophenolate Mofetil in Congenital Uropathies
NCT00193635 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
NCT03598036 ·Status: TERMINATED ·Phase: PHASE2
-
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
NCT03523728 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05510115 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
NCT04705051 ·Status: TERMINATED ·Phase: PHASE3
-
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558 ·Status: RECRUITING ·Phase: PHASE2
-
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
NCT06748040 ·Status: COMPLETED ·Phase: NA
-
Study of Lanreotide to Treat Polycystic Kidney Disease
NCT01616927 ·Status: UNKNOWN ·Phase: PHASE3
-
Antiproteinuric Agents and Fabry Disease
NCT00343577 ·Status: COMPLETED
-
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease
NCT01156428 ·Status: COMPLETED
-
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
NCT04069260 ·Status: TERMINATED ·Phase: PHASE2
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
NCT01581424 ·Status: RECRUITING
-
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
NCT05517980 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
NCT00872729 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rutgers University Study of the Genetics of Kidney Disease
NCT07217535 ·Status: RECRUITING